Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinica
Novartis Is Maintained at Buy by Jefferies
Novartis Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on Novartis, Raises Price Target to $122.5
Jefferies analyst Peter Welford maintains Novartis (NYSE:NVS) with a Buy and raises the price target from $121 to $122.5.
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 15.08% Jefferies $121 → $122.5 Maintains Buy 04/24/2024 8.97% BMO Capital $114 → $116 Maintains
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
On Tuesday, a federal judge in Mississippi reportedly upheld a state law mandating drugmakers to provide discounts on medications dispensed by third-party pharmacies contracting with hospitals and cli
Novartis AG (NOVN) Gets a Buy From Deutsche Numis
Jefferies Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $122.5
Jefferies analyst Peter Welford maintains $Novartis AG(NVS.US)$ with a buy rating, and adjusts the target price from $121 to $122.5.According to TipRanks data, the analyst has a success rate of 52.7%
Express News | Novartis has started construction of a nuclear medicine factory in China with a planned investment of 600 million yuan.
Buy Rating for Novartis AG on Strong Sales and Robust Operating Performance
Express News | Novartis AG : Jefferies Raises Target Price to $122.5 From $121
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments
Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The
Goldman Sachs Sticks to Their Buy Rating for Novartis AG (NOVN)
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Exsilio Therapeutics Launches With $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, In
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
Nestle Carefully Targets Weight-Loss Drug Users With New Food Line
Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. The Euro
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.Mul
What's Going On With Neurological Disease Focused Trevena On Thursday?
Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.The company released preclinical data from two separate researc
Here's Why Novartis (NVS) Is a Strong Momentum Stock
MorphoSys Set to Delist Following Acquisition by Novartis
MorphoSys (MOR) said early Thursday it entered into a delisting agreement following the closing of its acquisition by Novartis (NVS) in May. The companies intend to merge MorphoSys into Novartis by "i